135 related articles for article (PubMed ID: 36442189)
1. The efficacy of low molecular weight heparin is reduced in COVID-19.
Watson O; Zaldua JC; Pillai S; Whitley J; Howard M; Lawrence M; Hawkins K; Morris K; Evans PA
Clin Hemorheol Microcirc; 2023; 84(3):333-344. PubMed ID: 36442189
[TBL] [Abstract][Full Text] [Related]
2. Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG - RAPID Trial): A structured summary of a study protocol for a randomised controlled trial.
Sholzberg M; Tang GH; Negri E; Rahhal H; Kreuziger LB; Pompilio CE; James P; Fralick M; AlHamzah M; Alomran F; Tseng E; Lim G; Lillicrap D; Carrier M; Áinle FN; Beckett A; da Costa BR; Thorpe K; Middeldorp S; Lee A; Cushman M; Jüni P
Trials; 2021 Mar; 22(1):202. PubMed ID: 33691765
[TBL] [Abstract][Full Text] [Related]
3. Low-molecular-weight heparin use in coronavirus disease 2019 is associated with curtailed viral persistence: a retrospective multicentre observational study.
Pereyra D; Heber S; Schrottmaier WC; Santol J; Pirabe A; Schmuckenschlager A; Kammerer K; Ammon D; Sorz T; Fritsch F; Hayden H; Pawelka E; Krüger P; Rumpf B; Traugott MT; Glaser P; Firbas C; Schörgenhofer C; Seitz T; Karolyi M; Pabinger I; Brostjan C; Starlinger P; Weiss G; Bellmann-Weiler R; Salzer HJF; Jilma B; Zoufaly A; Assinger A
Cardiovasc Res; 2021 Dec; 117(14):2807-2820. PubMed ID: 34609480
[TBL] [Abstract][Full Text] [Related]
4. Fractal dimension: a novel clot microstructure biomarker use in ST elevation myocardial infarction patients.
Lawrence MJ; Sabra A; Thomas P; Obaid DR; D'Silva LA; Morris RH; Hawkins K; Brown MR; Williams PR; Davidson SJ; Chase AJ; Smith D; Evans PA
Atherosclerosis; 2015 Jun; 240(2):402-7. PubMed ID: 25890059
[TBL] [Abstract][Full Text] [Related]
5. Antithrombin-independent anticoagulation by hypersulfated low-molecular-weight heparin.
Fredenburgh JC; Anderson JA; Weitz JI
Trends Cardiovasc Med; 2002 Oct; 12(7):281-7. PubMed ID: 12458089
[TBL] [Abstract][Full Text] [Related]
6. Low molecular weight heparin for prevention of central venous catheter-related thrombosis in children.
Pelland-Marcotte MC; Amiri N; Avila ML; Brandão LR
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD005982. PubMed ID: 32557627
[TBL] [Abstract][Full Text] [Related]
7. In vitro comparison of dabigatran, unfractionated heparin, and low-molecular-weight heparin in preventing thrombus formation on mechanical heart valves.
Maegdefessel L; Linde T; Krapiec F; Hamilton K; Steinseifer U; van Ryn J; Raaz U; Buerke M; Werdan K; Schlitt A
Thromb Res; 2010 Sep; 126(3):e196-200. PubMed ID: 20659761
[TBL] [Abstract][Full Text] [Related]
8. Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin.
Mousa SA; Linhardt R; Francis JL; Amirkhosravi A
Thromb Haemost; 2006 Dec; 96(6):816-21. PubMed ID: 17139378
[TBL] [Abstract][Full Text] [Related]
9. Low-molecular-weight heparin compared with unfractionated heparin in critically ill COVID-19 patients.
Volteas P; Drakos P; Alkadaa LN; Cleri NA; Asencio AA; Oganov A; Giannopoulos S; Saadon JR; Mikell CB; Rubano JA; Labropoulos N; Tassiopoulos AK; Mofakham S; Bannazadeh M
J Vasc Surg Venous Lymphat Disord; 2022 Sep; 10(5):1128-1136. PubMed ID: 35716998
[TBL] [Abstract][Full Text] [Related]
10. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
Holzheimer RG
Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
[TBL] [Abstract][Full Text] [Related]
11. New-generation anticoagulants: the low molecular weight heparins.
Hovanessian HC
Ann Emerg Med; 1999 Dec; 34(6):768-79. PubMed ID: 10577408
[TBL] [Abstract][Full Text] [Related]
12. Low Molecular Weight Heparin, Anti-inflammatory/Immunoregulatory and Antiviral Effects, a Short Update.
Vitiello A; Ferrara F
Cardiovasc Drugs Ther; 2023 Apr; 37(2):277-281. PubMed ID: 34460031
[TBL] [Abstract][Full Text] [Related]
13. The Association of Low Molecular Weight Heparin Use and In-hospital Mortality Among Patients Hospitalized with COVID-19.
Shen L; Qiu L; Liu D; Wang L; Huang H; Ge H; Xiao Y; Liu Y; Jin J; Liu X; Wang DW; Peterson ED; He B; Zhou N
Cardiovasc Drugs Ther; 2022 Feb; 36(1):113-120. PubMed ID: 33394360
[TBL] [Abstract][Full Text] [Related]
14. Heparin and low molecular weight heparin in thrombosis and beyond.
Mousa SA
Curr Opin Investig Drugs; 2002 Aug; 3(8):1181-6. PubMed ID: 12211411
[TBL] [Abstract][Full Text] [Related]
15. Low molecular weight heparin is useful in adult COVID-19 inpatients. Experience during the first Spanish wave: observational study.
Gonzalez-Porras JR; Belhassen-Garcia M; Lopez-Bernus A; Vaquero-Roncero LM; Rodriguez B; Carbonell C; Azibeiro R; Hernandez-Sanchez A; Martin-Gonzalez JI; Manrique JM; Alonso-Claudio G; Alvarez-Navia F; Madruga-Martin JI; Macias-Casanova RP; García-Criado J; Lozano F; Moyano JC; Sanchez-Hernandez MV; Sagredo-Meneses V; Borras R; Bastida JM; Hernández-Pérez G; Chamorro AJ; Marcos M; Martin-Oterino JA
Sao Paulo Med J; 2022; 140(1):123-133. PubMed ID: 34406312
[TBL] [Abstract][Full Text] [Related]
16. Low-dose low-molecular-weight heparin is anti-inflammatory during venous thrombosis.
Downing LJ; Strieter RM; Kadell AM; Wilke CA; Greenfield LJ; Wakefield TW
J Vasc Surg; 1998 Nov; 28(5):848-54. PubMed ID: 9808852
[TBL] [Abstract][Full Text] [Related]
17. Preoperative low molecular weight heparin reduces heparin responsiveness during cardiac surgery.
Bar-Yosef S; Cozart HB; Phillips-Bute B; Mathew JP; Grocott HP
Can J Anaesth; 2007 Feb; 54(2):107-13. PubMed ID: 17272249
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis. Certoparin-Study Group.
Kirchmaier CM; Wolf H; Schäfer H; Ehlers B; Breddin HK
Int Angiol; 1998 Sep; 17(3):135-45. PubMed ID: 9821025
[TBL] [Abstract][Full Text] [Related]
19. The Cross-Talk between Thrombosis and Inflammatory Storm in Acute and Long-COVID-19: Therapeutic Targets and Clinical Cases.
Acanfora D; Acanfora C; Ciccone MM; Scicchitano P; Bortone AS; Uguccioni M; Casucci G
Viruses; 2021 Sep; 13(10):. PubMed ID: 34696334
[TBL] [Abstract][Full Text] [Related]
20. Studies comparing low molecular weight heparin with heparin for the treatment of thromboembolism: a literature review.
Messmore HL; Coyne E; Wehrmacher WH; Demir AM; Fareed J
Curr Pharm Des; 2004; 10(9):1001-10. PubMed ID: 15078129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
